Lighthouse Pharmaceuticals received nearly $50 million from the NIH’s National Institute on Aging to support a phase 2 trial targeting bacterial involvement in Alzheimer's associated with Porphyromonas gingivalis infection. Parallel research highlights a novel neuroprotective role of midkine protein in attenuating amyloid beta fibril formation, providing new angles for therapeutic intervention. These findings emphasize evolving multi-modal strategies beyond amyloid targeting in Alzheimer’s disease treatment.